Evaluating Blood Markers to Monitor Treatment Success in Postmenopausal Women with Osteoporosis Randomized Trial Comparing Bone-Building and Bone-Slowing Drugs with Calcium and Vitamin D

What this Trial Is About

Researchers are evaluating the use of blood tests called Bone Turnover Markers BTMs to quickly monitor how well osteoporosis treatments are working in postmenopausal women. Osteoporosis weakens bones and raises fracture risk. Current monitoring with DEXA scans measures bone density but changes slowly. This study compares BTMs and bone density changes over six months in women receiving different osteoporosis drugs to see if BTMs can provide earlier treatment feedback, which is especially helpful where repeat DEXA scans are hard to access. In this randomized controlled trial, 40 postmenopausal women over 50 with osteoporosis will be randomly assigned to two groups. One group will receive anabolic therapy with Teriparatide injections daily for six months, plus calcium and vitamin D supplements. The other group will receive oral antiresorptive drugseither Alendronate weekly, Ibandronate monthly, or Risedronate monthlyalong with calcium and vitamin D supplementation. The study will measure changes in specific BTMs and bone mineral density at set intervals. Participants will be monitored at the start, three months, and six months to assess BTMs, and bone density will be measured at baseline and six months. Researchers will also track new fractures and quality of life. The trial includes detailed evaluations of bone metabolism markers and bone strength to understand treatment responses, with the goal of improving osteoporosis management in clinical settings like Pakistan. The total study duration for participants is six months.

Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis